Catalio Capital Management
Catalio Capital Management is a Venture capital investments in breakthrough biomedical technology companies.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Catalio Capital Management Information
Geographic Data
Address: 500 East Pratt Street
City: Baltimore
State: MD
Zip: 21202
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$566M
Social
Twitter
Linkedin
Crunchbase
Metrics
3,481,207Website Global Rank
4,096Website Monthly Traffic
Twitter Followers
Description
Catalio Capital Management is a Venture capital investments in breakthrough biomedical technology companies.
Contact Phone:
+14109896168
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2022 | Anagenex | Series A | 0 |
| 12/2020 | Faze Medicines | Series A | 81M |
| 3/2021 | ATAI Life Sciences | Series D | 0 |
| 3/2022 | Satellite Bio | Series A | 0 |
| 4/2022 | Octant Bio | Series B | 80M |
| 11/2022 | Medical Informatics | Debt Financing | 10M |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 3/2022 | Sherlock Biosciences | Series B | 0 |
| 1/2021 | Paige | Series C | 125M |
| 8/2020 | Freenome | Series C | 270M |
| 2/2021 | Immunai | Series A | 60M |
| 2/2021 | Cambrian Biopharma | Series B | 0 |
| 1/2021 | Sensei Biotherapeutics | Series B | 0 |
| 10/2021 | DNA Script | Series C | 0 |
| 12/2021 | Freenome | Series D | 300M |
| 3/2022 | PrognomiQ | Venture Round | 0 |
| 7/2021 | Xilis | Series A | 0 |
| 4/2022 | Octant Bio | Series B | 0 |
| 1/2022 | Septerna | Series A | 100M |
| 11/2022 | Medical Informatics | Series B | 0 |
| 1/2021 | SetPoint Medical | Venture Round | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 6/2021 | Enveda Biosciences | Series A | 51M |
| 3/2021 | EGenesis | Series C | 0 |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 1/2023 | SetPoint Medical | Venture Round | 0 |
| 2/2021 | Personal Genome Diagnostics | Series C | 0 |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 12/2021 | Hyperfine | Post-IPO Equity | 0 |
| 3/2023 | Volastra Therapeutics | Series A | 0 |
| 7/2020 | Glympse Bio | Series B | 46.7M |
| 1/2023 | Spiral Therapeutics | Venture Round | 8.3M |
| 12/2022 | ArriVent Biopharma | Series B | 0 |
| 9/2022 | Proto Axiom | Series A | 9.7M |
| 1/2023 | Metagenomi | Series B | 0 |
| 8/2020 | Fractyl Health | Series E | 0 |
| 1/2022 | DNA Script | Series C | 0 |
| 7/2021 | Bayesian Health | Venture Round | 0 |
| 8/2022 | Fractyl Health | Series F | - |
| 11/2020 | ATAI Life Sciences | Series C | 0 |
| 1/2023 | Perceive Biotherapeutics | Series B | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 4/2021 | Volastra Therapeutics | Seed | 32M |
| 7/2021 | Entos | Series A | 0 |
| 5/2022 | Character Biosciences | Series A | 0 |
| 3/2022 | RefleXion Medical | Venture Round | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | Anagenex | Series A | 0 |
| 5/2022 | Character Biosciences | Series A | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 4/2022 | Octant Bio | Series B | 0 |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 3/2022 | PrognomiQ | Venture Round | 0 |
| 3/2022 | RefleXion Medical | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
